4.6 Article

Prognostic value of pulse pressure after an acute coronary syndrome

期刊

ATHEROSCLEROSIS
卷 277, 期 -, 页码 219-226

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2018.07.013

关键词

Aortic stiffness; Pulse pressure; Acute coronary syndrome; Prognosis; Cardiovascular events

资金

  1. Swiss National Science Foundation [SPUM 33CM30-124112, SPUM 33CM30-140 336]
  2. Roche Diagnostics
  3. Eli Lilly
  4. AstraZeneca
  5. Medtronic
  6. Merck Sharpe and Dome (MSD)
  7. Sanofi-Aventis
  8. St. Jude Medical
  9. Zurich Heart House - Foundation for Cardiovascular Research, Zurich, Switzerland

向作者/读者索取更多资源

Background and aims: Pulse pressure (PP) is a surrogate of aortic stiffness (AS) easily obtainable. The link between AS and cardio-vascular disease is documented, however, data regarding acute coronary syndrome (ACS) patients are scarce and contradictory. We aimed to assess the prognostic value of PP measured at admission, with regard to major adverse outcomes (all-cause mortality, recurrence of MI, and stroke), during the first year following an acute coronary syndrome (ACS). Methods: The SPUM-ACS project is a prospective cohort study of patients with ACS conducted in 4 Swiss University hospitals. Patients with no PP at admission or with severe clinical heart failure or cardiogenic shock were excluded. Cox regression analyses were performed to determine associations between PP and outcomes (all-cause mortality, recurrence of myocardial infarction (MI), and stroke). Three multivariate Cox regression models were adjusted for hemodynamic, cardiovascular, and non-cardiovascular confounders, added successively. Results: Of 5635 eligible patients, 5070 met the inclusion criteria. Mean patient age was 63 years (range: 54-72), 79.6% were male, and mean blood pressure and PP were 93.9 +/- 15.6 and 54 +/- 17 mmHg, respectively. Multivariate analyses confirmed the prognostic significance of PP for each 10-mmHg increase for the composite endpoint, hazard ratio (HR) 1.126 [1.051-1.206], p = 0.001; all-cause mortality, HR1.129 [1.013-1.260], p = 0.029; and recurrence of MI, HR1.206 [1.102-1.320], p < 0.001; but not for stroke, HR1.014[0.853-1.205]. Conclusions: PP measured at admission is a strong, independent prognostic marker predicting mortality and recurrence of MI after ACS. PP should be considered for the management of secondary prevention. (c) 2018 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据